EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $419,420 | $876,118 | $130,610 | $351,998 |
| - Cash | $99,704 | $281,263 | $95,633 | $178,593 |
| + Debt | $21,858 | $4,906 | $46,348 | $39,204 |
| Enterprise Value | $341,574 | $599,761 | $81,325 | $212,609 |
| Revenue | $43,273 | $46,018 | $41,404 | $36,939 |
| % Growth | -6% | 11.1% | 12.1% | – |
| Gross Profit | $39,561 | $41,386 | $33,078 | $28,762 |
| % Margin | 91.4% | 89.9% | 79.9% | 77.9% |
| EBITDA | -$129,226 | -$69,001 | -$96,619 | -$50,148 |
| % Margin | -298.6% | -149.9% | -233.4% | -135.8% |
| Net Income | -$130,870 | -$70,795 | -$102,254 | -$58,417 |
| % Margin | -302.4% | -153.8% | -247% | -158.1% |
| EPS Diluted | -2.32 | -1.82 | -2.74 | -2.03 |
| % Growth | -27.5% | 33.6% | -35% | – |
| Operating Cash Flow | -$126,226 | $1,875 | -$65,005 | -$50,097 |
| Capital Expenditures | -$4,052 | -$3,483 | -$2,150 | -$156 |
| Free Cash Flow | -$130,278 | -$1,608 | -$67,155 | -$50,253 |